查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585642

生技藥品合約開發市場：按來源、類型、適應症、階段、服務類型、最終用戶 - 2025-2030 年全球預測

Biologics Contract Development Market by Source (Mammalian, Microbial), Type (Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins), Disease Indication, Phase, Service Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生技藥品合約開發市場價值為65.4億美元，預計到2024年將達到73億美元，複合年成長率為11.79%，到2030年將達到142.8億美元。

生技藥品合約開發包括由專業公司提供的服務，協助生物技術和製藥公司開發生物製藥，包括單株抗體、疫苗、細胞療法和基因療法。由於與生物製藥開發相關的複雜而嚴格的監管要求，該領域變得越來越必要。應用跨越細胞株開發、製程最佳化和放大生產等各個階段，並涉及生物製藥和生物技術等產業。慢性病盛行率的上升、生物技術的進步以及對個人化醫療日益成長的興趣推動了市場對先進生物治療的需求。關鍵的成長要素包括研發活動的活性化、政府對生技藥品開發的大力資助以及生物加工的技術創新。新的商機在於採用一次性技術來提高製程效率並減少交叉污染，以及成本敏感市場對生物相似藥不斷成長的需求。

主要市場統計
基準年[2023] 65.4億美元
預測年份 [2024] 73億美元
預測年份 [2030] 142.8億美元
複合年成長率（%） 11.79%

然而，這種情況並非沒有挑戰。生技藥品開發的高成本、技術人員的有限以及嚴格的法律規範可能會阻礙市場擴張。此外，智慧財產權問題和放大過程的複雜性也是主要障礙。人工智慧和機器學習的整合等創新可以最佳化開發流程並縮短上市時間，為業務成長提供了一條充滿希望​​的道路。此外，探索新的表現系統和提高生物過程效率將是研究和創新的重要領域。該市場的特點是競爭激烈且分散，主要企業專注於策略聯盟、收購和投資，以加強其服務產品並擴大其全球業務。為了保持成長並捕捉市場格局中的新興趨勢，尋求利用市場機會的公司需要投資最尖端科技、培育合資企業並積極應對監管環境。

市場動態：快速發展的生技藥品合約開發市場的關鍵市場洞察

合約生技藥品開發市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 疫苗和生物相似藥製造的需求增加
    • 政府鼓勵生技藥品活動的舉措
    • 利用生技藥品CDO 提高業務效率並降低成本
  • 市場限制因素
    • 最終使用者和 CDO 之間的溝通問題
  • 市場機會
    • 生技藥品開發系統的技術進步
    • 投資擴大新生技藥品合約開發服務
  • 市場挑戰
    • 對知識產權侵權的擔憂

波特五力：駕馭生技藥品合約開發市場的策略工具

波特的五力架構是了解生技藥品合約開發市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生技藥品合約開發市場的外部影響

外部宏觀環境因素在塑造生技藥品合約開發市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解生技藥品合約開發市場的競爭狀況

生技藥品合約開發市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生技藥品合約開發市場供應商績效評估

FPNV定位矩陣是評估生技藥品合約開發市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製合約生技藥品開發市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對生技藥品合約開發市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 疫苗和生物相似藥生產的需求增加
      • 政府鼓勵生技藥品活動的舉措
      • 利用生物製劑 CDO 提高業務效率並降低成本
    • 抑制因素
      • 最終使用者和 CDO 之間的溝通問題
    • 機會
      • 生物製藥開發系統的技術進步
      • 投資擴大新生技藥品的合約開發服務
    • 任務
      • 對知識產權侵權的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章生技藥品合約開發市場：依來源分類

  • 哺乳動物的
  • 微生物

第7章生技藥品合約開發市場：按類型

  • 分子治療
  • 單株抗體
  • 重組蛋白
  • 疫苗

第8章生技藥品合約開發市場：依疾病適應症

  • 心血管疾病
  • 血液疾病
  • 免疫疾病
  • 腫瘤學

第9章生技藥品合約開發市場分階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前

第10章生技藥品合約開發市場：依服務類型

  • 細胞株開發
    • 哺乳動物的
    • 微生物
  • 製程開發
    • 下游
      • 雜質、分離、鑑定
      • 藥物分析
      • 理化表徵
    • 上游
      • 哺乳動物的
      • 微生物

第11章生技藥品合約開發市場：依最終用戶分類

  • 生物製藥公司
  • 研究室

第12章美洲生技藥品合約開發市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太生技藥品合約開發市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲的生技藥品合約開發市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JRS PHARMA GmbH & Co. KG
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc.
Product Code: MRR-957C47F8FF75

The Biologics Contract Development Market was valued at USD 6.54 billion in 2023, expected to reach USD 7.30 billion in 2024, and is projected to grow at a CAGR of 11.79%, to USD 14.28 billion by 2030.

Biologics Contract Development encompasses services provided by specialized companies to assist biotechnology and pharmaceutical firms in the development of biological products, including monoclonal antibodies, vaccines, cell therapies, and gene therapies. This sector is increasingly necessary due to the complexity and stringent regulatory requirements associated with biologic drug development. Applications span across various stages, such as cell line development, process optimization, and scale-up production, catering to industries like biopharmaceuticals and biotechnology. The market is buoyed by the rising prevalence of chronic diseases, advancements in biotechnology, and an increasing focus on personalized medicine, driving the demand for sophisticated biologic therapies. Key growth factors include intensifying research and development activities, robust government funding for biologics development, and technological innovations in bioprocessing. Emerging opportunities lie in the adoption of single-use technologies, which enhance process efficiency and reduce cross-contamination, as well as escalating demand for biosimilars in cost-sensitive markets.

KEY MARKET STATISTICS
Base Year [2023] USD 6.54 billion
Estimated Year [2024] USD 7.30 billion
Forecast Year [2030] USD 14.28 billion
CAGR (%) 11.79%

However, the landscape is not without challenges. High costs associated with biologics development, limited availability of skilled personnel, and stringent regulatory frameworks can hinder market expansion. Moreover, intellectual property issues and the complexity of scale-up processes pose significant barriers. Innovations such as the integration of artificial intelligence and machine learning for optimizing development processes and reducing time-to-market present promising avenues for business growth. Additionally, exploring novel expression systems and enhancing bioprocess efficiency provide areas for significant research and innovation. The market is characterized by a competitive and fragmented nature, with key players focusing on strategic partnerships, acquisitions, and investments to enhance their service offerings and expand their global footprint. Companies aiming to capitalize on market opportunities should invest in cutting-edge technologies, foster collaborative ventures, and address regulatory challenges proactively to sustain growth and capture emerging trends in the biologics contract development landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Development Market

The Biologics Contract Development Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for vaccine and biosimilar production
    • Government initiatives encouraging biologics activities
    • Improved operational efficiency and cost saving with biologics CDO
  • Market Restraints
    • Communication issues between end-user and CDO
  • Market Opportunities
    • Technological advancements in biologics development systems
    • Investments in new biologics contract development services expansion
  • Market Challenges
    • Concerns associated with breach of intellectual property

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Development Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Development Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Development Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Development Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Development Market

A detailed market share analysis in the Biologics Contract Development Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Development Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Development Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Development Market

A strategic analysis of the Biologics Contract Development Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Development Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JRS PHARMA GmbH & Co. KG, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Development Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Mammalian and Microbial.
  • Based on Type, market is studied across Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins, and Vaccines.
  • Based on Disease Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, and Oncology.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Preclinical.
  • Based on Service Type, market is studied across Cell Line Development and Process Development. The Cell Line Development is further studied across Mammalian and Microbial. The Process Development is further studied across Downstream and Upstream. The Downstream is further studied across Impurity, Isolation, & Identification, Pharmaceutical Analysis, and Physicochemical Characterization. The Upstream is further studied across Mammalian and Microbial.
  • Based on End-User, market is studied across Biopharmaceutical Companies and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for vaccine and biosimilar production
      • 5.1.1.2. Government initiatives encouraging biologics activities
      • 5.1.1.3. Improved operational efficiency and cost saving with biologics CDO
    • 5.1.2. Restraints
      • 5.1.2.1. Communication issues between end-user and CDO
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in biologics development systems
      • 5.1.3.2. Investments in new biologics contract development services expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with breach of intellectual property
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Contract Development Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Microbial

7. Biologics Contract Development Market, by Type

  • 7.1. Introduction
  • 7.2. Molecular Therapy
  • 7.3. Monoclonal Antibodies
  • 7.4. Recombinant Proteins
  • 7.5. Vaccines

8. Biologics Contract Development Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Oncology

9. Biologics Contract Development Market, by Phase

  • 9.1. Introduction
  • 9.2. Phase I
  • 9.3. Phase II
  • 9.4. Phase III
  • 9.5. Preclinical

10. Biologics Contract Development Market, by Service Type

  • 10.1. Introduction
  • 10.2. Cell Line Development
    • 10.2.1. Mammalian
    • 10.2.2. Microbial
  • 10.3. Process Development
    • 10.3.1. Downstream
      • 10.3.1.1. Impurity, Isolation, & Identification
      • 10.3.1.2. Pharmaceutical Analysis
      • 10.3.1.3. Physicochemical Characterization
    • 10.3.2. Upstream
      • 10.3.2.1. Mammalian
      • 10.3.2.2. Microbial

11. Biologics Contract Development Market, by End-User

  • 11.1. Introduction
  • 11.2. Biopharmaceutical Companies
  • 11.3. Research Laboratories

12. Americas Biologics Contract Development Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Biologics Contract Development Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Biologics Contract Development Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Abzena Ltd.
  • 3. Aenova Holding GmbH
  • 4. AGC Biologics GmbH
  • 5. Avid Bioservices, Inc.
  • 6. Binex Co. Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Cambrex Corporation
  • 9. Catalent, Inc.
  • 10. Emergent BioSolutions, Inc.
  • 11. Fujifilm Holdings Corporation
  • 12. Icon PLC
  • 13. JRS PHARMA GmbH & Co. KG
  • 14. JSR Life Sciences, LLC
  • 15. Lonza Group AG
  • 16. Parexel International Corporation
  • 17. ProBioGen AG
  • 18. Recipharm AB
  • 19. Rentschler Biopharma SE
  • 20. Samsung Biologics
  • 21. Takeda Pharmaceutical Company Limited
  • 22. Thermo Fisher Scientific, Inc.
  • 23. Toyobo Co., Ltd.
  • 24. WuXi Biologics Inc.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS CONTRACT DEVELOPMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY IMPURITY, ISOLATION, & IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHYSICOCHEMICAL CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (US